MARC Record from marc_columbia

LEADER: 20847cam a2200457 a 4500
001 8212172
005 20221201060414.0
008 100311t20112011flua b 001 0 eng
010 $a 2010010721
016 7 $a101526290$2DNLM
019 $a526106602
020 $a9781439821060 (alk. paper)
020 $a1439821062 (alk. paper)
029 1 $aNLM$b101526290
035 $a(OCoLC)ocn559647374
035 $a(OCoLC)559647374$z(OCoLC)526106602
035 $a(NNC)8212172
035 $a8212172
040 $aDNLM/DLC$cDLC$dYDX$dBTCTA$dNLM$dYDXCP$dCDX$dOrLoB-B
042 $apcc
050 00 $aRB170$b.P737 2011
060 10 $aQU 130.5$bP911m 2011
082 00 $a613.2/86$222
100 1 $aPrasad, Kedar N.$0http://id.loc.gov/authorities/names/n79076682
245 10 $aMicronutrients in health and disease /$cKedar N. Prasad.
260 $aBoca Raton :$bCRC Press,$c[2011], ©2011.
300 $axxv, 365 pages :$billustrations ;$c27 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 00 $gChapter 1.$tBasic Facts about Antioxidants -- $tIntroduction -- $tEvolution of the Antioxidant System -- $tHistory of the Discovery of Antioxidants -- $tSources and Forms of Vitamins -- $tSolubility of Antioxidants -- $tDistribution of Antioxidants in the Body -- $tStorage of Antioxidants -- $tCan Antioxidants Be Degraded during Cooking? -- $tAbsorption of Antioxidants and Its Significance -- $tFunctions of Individual Antioxidants -- $tAntioxidant Defense Systems -- $gGroup A.$tAntioxidants -- $gGroup B.$tAntioxidants -- $gGroup C.$tAntioxidants -- $tKnown Functions of Antioxidants -- $tCurrent Controversies about Antioxidants -- $tMisuse of Antioxidants in Clinical Studies -- $tConclusions -- $tReferences -- $gChapter 2.$tBasic Facts about Oxidative Stress, Inflammation, and the Immune System -- $tIntroduction -- $tOxidative Stress -- $tWhat are Free Radicals? -- $tTypes of Free Radicals -- $tFormation of Free Radicals Derived from Oxygen and Nitrogen -- $tOxidation and Reduction Processes -- $tWhat is Inflammation? -- $tTypes of Inflammatory Reactions -- $tProducts of Inflammatory Reactions -- $tCytokines -- $tComplement Proteins -- $tAA Metabolites -- $tEndothelial/Leukocyte Adhesion Molecules -- $tImmune System -- $tWhat is the Immune System? -- $tInnate Immunity -- $tAdaptive Immunity -- $tConclusions -- $tReferences -- $gChapter 3.$tScientific Rationale of Current Trends in Clinical Studies of Micronutrients for Prevention of Chronic Diseases -- $tIntroduction -- $tLevels of Oxidative Stress and Chronic Inflammation in High-Risk Populations -- $tHigh-Risk Populations for Cancer -- $tHigh-Risk Populations of CAD -- $tHigh-Risk Populations of AD and PD -- $tBiology of Antioxidants -- $tResults of Clinical Trials with a Single Antioxidant -- $tCancer -- $tCoronary Artery Disease -- $tAlzheimer's Disease and Parkinson's Disease -- $tReasons the Use of a Single Antioxidant Produced Inconsistent Results -- $tResults of Clinical Studies with Multiple Dietary Antioxidants in Cancer -- $tResults of Clinical Studies with Fat and Fiber -- $tUsing Multiple Micronutrients with a Low-Fat, High-Fiber Diet to Reduce the Risk and Progression of Chronic Diseases -- $tRecommended Micronutrients for Reducing the Risk and Progression of Chronic Diseases -- $tConclusions -- $tReferences -- $gChapter 4.$tMicronutrients in Healthy Aging -- $tIntroduction -- $tOxidative Stress during Aging -- $tSources of Oxidative Stress -- $tInfluence of Environmental, Dietary, Metabolic, and Lifestyle-Related Stressors on Oxidative Stress -- $tOxidative Stress Influences Mitochondria, Lysosome, and Proteasome Function during Aging -- $tMitochondrial Dysfunction -- $tImpairment of Proteasome and Lysosomal-Mediated Proteolytic Activities -- $tOxidative Stress Influences the Length of Telomere during Aging -- $tChronic Inflammation during Aging -- $tAging Influences Immune Function -- $tAging Influencing Antioxidant Defense Systems -- $tAntioxidant Enzymes -- $tChanges in Antioxidant Enzyme Activities in Animals -- $tChanges in Antioxidant Enzyme Activities in Humans -- $tDietary and Endogenous Antioxidants Levels -- $tVitamin C -- $tGlutathione -- $tVitamin E -- $tCoenzyme Q10 -- $tAntioxidant Supplementation Influences Age-Related Functional Deficits -- $tVitamin E -- $tCoenzyme Q10 -- $tCarotenoids -- $tMelatonin -- $tFlavonoids -- $tGlutathione and N-Acetylcysteine -- $tAlpha-Lipoic Acid -- $tMultiple Dietary Antioxidants -- $tRationale for Not Using a Single Dietary Antioxidant to Reduce Age-Related Functional Deficits -- $tRationale for Recommending Multiple Micronutrients to Reduce the Rate of Aging -- $tRecommended Micronutrients for Adults and Children -- $tChanges in Diet and Lifestyle -- $tConclusions -- $tReferences -- $gChapter 5.$tRole of Micronutrients in the Prevention of Coronary Artery Disease and Improvement of the Standard Therapy -- $tIntroduction -- $tIncidence and Cost -- $tPrimary Risk Factors and Involvement of Oxidative Stress and Inflammation in CAD -- $tConsequences of Increased Oxidative Stress and Chronic Inflammation -- $tLow-Dose Aspirin in CAD -- $tRole of Antioxidants in CAD -- $tAnimal Studies after Treatment with Antioxidants -- $tEpidemiologic Studies with Antioxidants -- $tIntervention Human Studies after Treatment with One or More Dietary Antioxidants -- $tVitamin E Alone Producing Beneficial Effects -- $tVitamin C Alone Producing Beneficial Effects -- $tDietary Antioxidants Producing No Effects or Adverse Effects -- $tEndogenous Antioxidants Producing No Effect or Beneficial Effects -- $tDietary and Endogenous Antioxidants with Cholesterol-Lowering Drugs -- $tMultiple Dietary Antioxidants with Cholesterol-Lowering Drugs -- $tResveratrol and Omega-3 Fatty Acids -- $tResveratrol -- $tOmega-3 Fatty Acids -- $tIntervention Studies with B-Vitamins to Lower Homocysteine Levels -- $tScientific Rationale for Using Multiple Micronutrients Including Dietary and Endogenous Antioxidants in Prevention and Improved Treatment of CAD -- $tProposed Multiple Micronutrient Preparation -- $tImportance of Dose Schedule -- $tAntioxidants and Aspirin Resistance -- $tScientific Rationale for Using Multiple Micronutrient Preparations in Combination with Cholesterol-Lowering Drugs and Aspirin for Reducing the Progression of CAD -- $tModifications in Diet and Lifestyle -- $tConclusions -- $tReferences -- $gChapter 6.$tMicronutrients for the Prevention of Diabetes and Improvement of the Standard Therapy -- $tIntroduction -- $tIncidence and Cost -- $tTypes of Diabetes -- $gType 1.$tDiabetes -- $gType 2.$tDiabetes -- $tGestational Diabetes -- $tOther Types of Diabetes -- $tPrediabetes and Metabolic Syndrome -- $tComplications of Diabetes -- $tEvidence for Increased Oxidative Stress in Diabetes -- $gType 1.$tDiabetes -- $gType 2.$tDiabetes -- $tMetabolic Syndrome -- $tEvidence for Increased Chronic Inflammation in Diabetes -- $tBeneficial Effects of Antioxidants and Other Nutrients in Diabetes -- $tVitamin A -- $tVitamin C -- $tVitamin D -- $tVitamin E -- $tAlpha-Lipoic Acid -- $tN-Acetylcysteine -- $tL-Carnitine -- $tCoenzyme Q10 -- $tAntioxidant Mixtures -- $tVitamin A and Insulin -- $tFolic Acid and Thiamine -- $tChromium -- $tAntioxidants in Combination with Diabetic/Cardiovascular Drugs and/or Insulin -- $tOmega-3 Fatty Acids -- $tAnimal Studies -- $tHuman Epidemiologic Studies with Omega-3 Fatty Acids -- $tHuman Intervention Studies with Omega-3 Fatty Acids Alone -- $tHuman Studies with Omega-3 Fatty Acids, Antidiabetic Drugs and Heart Medications -- $tTreatments of Diabetes -- $tStandard Treatments -- $tAspirin -- $tAspirin Resistance -- $tAnimal Studies with Aspirin -- $tProblems Associated with Using a Single Agent in Diabetic Patients -- $tRationale for Using Multiple Micronutrients in Diabetic Patients -- $tRecommended Micronutrient Supplement for the Prevention of Diabetes in High-Risk Populations -- $tRecommended Micronutrient Supplement in Combination with Standard Therapy in Diabetic Patients -- $tDiet and Lifestyle Recommendations for Prediabetic Individuals and Diabetic Patients -- $tConclusions -- $tReferences -- $gChapter 7.$tMicronutrients in Cancer Prevention -- $tIntroduction -- $tCancer Incidence, Mortality, and Cost -- $tProposed Stages of Human Carcinogenesis -- $tDiagrammatic Representation of the Proposed Stages of Human Carcinogenesis -- $tSome Examples of Tumor Initiators and Tumor Promoters -- $tContribution of Environmental, Dietary, and Lifestyle-Related Factors -- $tSome Examples of Lifestyle-Related Carcinogens -- $tSome Examples of Environment-Related Carcinogens -- $tSome Examples of Diet-Related Carcinogens -- $tSome Examples of Diet-Related Cancer Protective Agents -- $tFunctions of Antioxidants Relevant to Cancer Prevention -- $tAnalysis of Cell Cultures after Treatment with Antioxidants -- $tAnalysis of Cancer Prevention Studies in Animals after Treatment with Antioxidants -- $tAnalysis of Epidemiologic Studies on Antioxidants and Cancer Prevention -- $tAnalysis of Intervention Studies on Antioxidants and Cancer Prevention -- $tCancer Risk in Heavy Tobacco Smokers after Treatment with a Single Dietary Antioxidant --
505 80 $tOther Cancer Risks after Treatment with a Single Dietary Antioxidant -- $tCancer Risk after Treatment with Multiple Dietary Antioxidants -- $tCancer Risk after Treatment with Vitamin D and Calcium -- $tCancer Risk after Treatment with Folate and B-Vitamins -- $tCancer Risk after Treatment with Fat and Fiber -- $tCancer Risk after Treatment with NSAIDs -- $tProposed Cancer Prevention Strategies -- $tRecommendations for Cancer-Free Normal Individuals -- $tRecommendations for Cancer-Free High-Risk Individuals -- $tRecommendations for Cancer Survivors -- $tDiet and Lifestyle Recommendations for Individuals of High-Risk Populations -- $tRationale for Using Multiple Micronutrients in Proposed Cancer Preventive Strategy -- $tUnique Features of Proposed Micronutrient Formulation -- $tToxicity of Micronutrients -- $tConclusions -- $tReferences -- $gChapter 8.$tMicronutrients for Improvement of the Standard Therapy in Cancer -- $tIntroduction -- $tPreventive and Therapeutic Dose Ranges of Antioxidants -- $tRecommendation by Oncologists and Use of Antioxidants by Their Patients -- $tEffects of Therapeutic Doses of Individual Antioxidants on Growth of Cancer and Normal Cells -- $tVitamin E and Its Derivatives -- $tVitamin C -- $tCombination of Vitamin C or Vitamin E with Other Agents -- $tVitamin A and Carotenoids -- $tSelenium -- $tMixture of Dietary Antioxidants -- $tNAC and Alpha-Lipoic Acid -- $tCoenzyme Q10 -- $tAntioxidant Enzymes -- $tTreatment Schedules -- $tEffects of Therapeutic Doses of Individual Antioxidants on Gene Expression Profiles in Cancer Cells -- $tEffects of Preventive Doses of Individual Antioxidants on Cancer Cell Growth -- $tEffects of Therapeutic Doses of Individual Antioxidants on Radiation-Induced Damage in Cancer Cells and Normal Cells -- $tCell Culture Studies -- $tAnimal Studies -- $tClinical Studies -- $tEffects of Therapeutic Doses of Individual Antioxidants on Chemotherapeutic Agent-Induced Damage in Cancer Cells and Normal Cells -- $tCell Culture Studies -- $tAnimal Studies -- $tClinical Studies -- $tGlutathione-Elevating Agents (NAC and Alpha-Lipoic Acid) -- $tCoenzyme Q10 -- $tVitamin E -- $tSelenium -- $tGlutamine -- $tMechanisms of Enhancing the Efficacy of Standard Therapy on Cancer Cells by Therapeutic Doses of Individual Antioxidants -- $tClinical Studies with Multiple Dietary Antioxidants -- $tRational for Using Multiple Micronutrients -- $tRationale for Not Recommending Antioxidant Supplements during Standard Therapy -- $tPreventive Doses of Individual Antioxidants Reduce the Efficacy of Cancer Therapeutic Agents -- $tUtilization of Data Obtained from the Use of Preventive Doses of Individual Antioxidants in High-Risk Populations -- $tUtilization of Data Obtained from the Use of Antioxidant Deficiency in Combination with Therapeutic Agents on Cancer Cells -- $tEffects of Therapeutic Doses of Individual Antioxidants in Combination with Experimental Cancer Therapies on Cancer Cells -- $tHyperthermia -- $tSodium Butyrate and Interferon-Alpha2b -- $tCellular Vaccine -- $tGene Therapy -- $tProposed Micronutrient Protocols -- $tAMTP Using Therapeutic Doses of Multiple Antioxidants -- $tPreventive Micronutrient Protocol Using Preventive Doses of Multiple Antioxidants -- $tRecommendations for Diet and Lifestyle Modifications -- $tConclusions -- $tReferences -- $gChapter 9.$tMicronutrients in the Prevention and Improvement of the Standard Therapy for Alzheimer's Disease -- $tIntroduction -- $tIncidence and Cost -- $tEtiology of AD -- $tNeuropathology of AD -- $tIncreased Oxidative Stress in AD -- $tSources of Free Radicals in Normal Brain -- $tFormation of Free Radicals Derived from Oxygen and Nitrogen -- $tOxidative Stress-Induced Mitochondrial Damage in AD -- $tBeta-Amyloid Mediates Its Neurotoxic Effects through Free Radicals in AD -- $tCholesterol-Induced Generation of Beta-Amyloid -- $tProteasome Inhibition Induced Neurodegeneration in AD -- $tGenetic Defects in Idiopathic AD -- $tMutated Genes Mediate their Effects through Increased Production of Beta-Amyloid in Familial AD -- $tIncreased Levels of Markers of Chronic Inflammation in AD -- $tNeuroglobin in AD -- $tCurrent Treatments of AD -- $tLaboratory and Clinical Studies with Antioxidants in AD -- $tAlpha-Lipoic Acid -- $tCoenzyme Q10 and Melatonin -- $tNicotinamide, Nicotinamide Adenine Dinucleotide (NAD+), and Nicotinamide Adenine Dinucleotide Dehydrogenase (NADH) -- $tVitamin A, Vitamin E, and Vitamin C -- $tSerum Levels of Dietary Antioxidants -- $tB-Vitamins -- $tResveratrol -- $tGinkgo biloba and Omega-3 Fatty Acids -- $tGreen Tea Epigallocatechin-3-Gallate and Caffeine -- $tProblems with Using a Single Nutrient in AD -- $tRationale for Using Multiple Micronutrients in AD -- $tRationale for Using NSAIDs in AD Prevention -- $tRecommended Micronutrients in Combination with Low-Doses of NSAIDs for Prevention of AD in High-Risk Populations -- $tRationale for Using Acetylcholinesterase Inhibitors in the Treatment of AD -- $tRecommended Micronutrients and Low-Dose NSAIDs with Standard Therapy in Patients with Dementia -- $tDiet and Lifestyle Recommendations for AD -- $tConclusions -- $tReferences -- $gChapter 10.$tMicronutrients for the Prevention and Improvement of the Standard Therapy for Parkinson's Disease -- $tIntroduction -- $tIncidence and Cost -- $tEtiology -- $tNeuropathology and Symptoms -- $tGenetics of PD -- $tDJ-1 Gene -- $tAlpha-Synuclein Gene -- $tPTEN-Induced Putative Kinase 1 -- $tIncreased Oxidative Stress in PD -- $tIncreased Inflammation in PD -- $tMitochondrial Dysfunction in PD -- $tLaboratory and Human Studies in PD with Antioxidants -- $tIn Vitro Studies -- $tStudies in Animal Models of PD -- $tStudies in Human PD -- $tProblems of Using a Single Antioxidant in PD -- $tRationale for Using Multiple Micronutrients in PD -- $tRationale for Using an NSAID in PD Prevention -- $tRecommended Micronutrient Supplement for Use in Combination with a Low-Dose NSAID for the Prevention of PD in High-Risk Populations -- $tRecommended Micronutrient Supplement for Use in Combination with a Low-Dose NSAID for Reducing the Rate of Progression of PD in Early-Stage Patients -- $tCurrent Treatments of PD -- $tRationale for Using a Micronutrient Supplement and an NSAID in Combination with Standard Therapy in PD Patients -- $tRecommended Micronutrient Supplement and Low-Dose NSAID in Combination with Standard Therapy in PD Patients -- $tDiet and Lifestyle Recommendations for PD -- $tConclusions -- $tReferences -- $gChapter 11.$tMicronutrients in Prevention and Improvement of the Standard Therapy in Hearing Disorders -- $tIntroduction -- $tIncidence and Cost -- $tTypes of Hearing Disorders -- $tConductive Hearing Loss -- $tSensorineural Hearing Loss -- $tTinnitus -- $tMeniere's Disease -- $tAgents or Conditions Causing Hearing Disorders -- $tMeasurements of Hearing Loss -- $tCurrent Prevention and Treatment Strategies -- $tInvolvement of Oxidative Stress in Hearing Disorders -- $tInvolvement of Inflammation in Hearing Disorders -- $tBeneficial Effects of Antioxidants in Hearing Disorders -- $tAnimal Studies -- $tHuman Studies -- $tRationale for Using Multiple Micronutrients in Hearing Disorders -- $tProposed Micronutrient Recommendation for Prevention and Improved Treatment of Hearing Disorders -- $tConclusions -- $tReferences -- $gChapter 12.$tMicronutrients in Improvement of the Standard Therapy in Posttraumatic Stress Disorder -- $tIntroduction -- $tIncidence and Cost of PTSD -- $tSymptoms of PTSD -- $tBiochemical Events in PTSD -- $tIncreased Oxidative Stress in PTSD -- $tChronic Inflammation in PTSD -- $tRelease of Glutamate in PTSD -- $tStandard Therapy in PTSD -- $tRationale for Using Micronutrients in PTSD -- $tProblems of Using a Single Micronutrient in PTSD -- $tRationale for Recommending Multiple Micronutrients Including Dietary and Endogenous Antioxidants in PTSD -- $tRecommended Micronutrients for Reducing the Risk of PTSD in High-Risk Populations -- $tRecommended Micronutrients in Combination with Standard Therapy in PTSD -- $tDiet and Lifestyle Recommendations for PTSD -- $tConclusions -- $tReferences --
505 80 $gChapter 13.$tMicronutrients in Improvement of the Standard Therapy in Traumatic Brain Injury -- $tIntroduction -- $tCauses of TBI -- $tIncidence and Cost of TBI -- $tU.S. Troops -- $tU.S. Civilians -- $tSymptoms and Consequences of TBI -- $tSymptoms and Consequences of Concussive Injury -- $tRisk of Posttraumatic Disorder Associated with TBI -- $tBiochemical Events that Contribute to the Progression of Damage Following TBI -- $tEvidence for Increased Oxidative Stress in TBI -- $tMitochondrial Dysfunction in TBI -- $tEvidence for Increased Levels of Markers of Inflammation in TBI -- $tEvidence for Increased Release of Glutamate in TBI -- $tRole of Matrix Metalloproteinases in TBI -- $tTreatments of TBI -- $tTreatments of Sports-Related Concussive Injury -- $tTreatments of TBI with Antioxidants -- $tAntioxidants Reduce Glutamate Release -- $tProblems of Using a Single Agent in TBI -- $tRationale for Using Multiple Micronutrients in TBI -- $tRecommended Micronutrients for Reducing the Late Adverse Effects in High-Risk Populations -- $tRecommended Micronutrient Supplement in Combination with Standard Therapy in TBI Patients with Penetrating Head Injury -- $tDiet and Lifestyle Recommendations for TBI -- $tConclusions -- $tReferences -- $gChapter 14.$tMicronutrients in Prevention and Improvement of the Standard Therapy in HIV/AIDS -- $tIntroduction -- $tHistory, Incidence, and Cost of HIV/AIDS -- $tRole of Immune Function in HIV Infection -- $tMicronutrient Deficiency Impairs Immune Function -- $tIllicit Drugs Impair Immune Function -- $tIncreased Oxidative Stress and Inflammation Enhance the Risk and Progression of HIV Infection -- $tCurrent and Proposed Prevention Strategies for HIV Infection -- $tPrimary Prevention -- $tSecondary Prevention -- $tEvidence for Micronutrients Reducing Progression of HIV Infection -- $tCurrent Treatments of HIV/AIDS -- $tRole of Micronutrients in Combination with Antiviral Drugs -- $tRationale for Using Multiple Micronutrients in Primary and Secondary Prevention of HIV Infection -- $tRecommended Micronutrients for Primary and Secondary Prevention of HIV Infection -- $tRecommended Micronutrients for Improving the Efficacy of Antiviral Therapy -- $tDiet and Lifestyle Recommendations -- $tConclusions -- $tReferences -- $gChapter 15.$tMicronutrients in Protecting Against Late Adverse Health Effects of Diagnostic Radiation Doses -- $tIntroduction -- $tProbable Biochemical and Genetic Steps Involved in Radiation-Induced Carcinogenesis -- $tInteractions between Radiation and Chemical and Biological Carcinogens and Tumor Promoters -- $tRisk Estimates of Radiation-Induced Cancer -- $tRisk of Low-Dose Radiation-Induced Non-Neoplastic Diseases.
650 0 $aAntioxidants$xHealth aspects.$0http://id.loc.gov/authorities/subjects/sh2009115041
650 0 $aActive oxygen$xPathophysiology.$0http://id.loc.gov/authorities/subjects/sh2009113511
650 0 $aTrace elements in nutrition.$0http://id.loc.gov/authorities/subjects/sh85136391
650 0 $aDietary supplements.$0http://id.loc.gov/authorities/subjects/sh85037861
650 12 $aMicronutrients$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D018977Q000627
650 22 $aAntioxidants$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D000975Q000627
650 22 $aDietary Supplements.$0https://id.nlm.nih.gov/mesh/D019587
852 00 $boff,hsl$hRB170$i.P737 2011